Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2023 18:00 ET | Source: Graphical Research

Actinic Keratosis Treatment Market to reach USD 9.7 billion by 2032, Says Graphical Research Powered by GMI

Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- Actinic Keratosis Treatment Market size to be worth USD 9.7 billion by 2032. The industry gains is driven by the increasing cases of...
August 03, 2022 12:30 ET | Source: Straits Research

Canine Atopic Dermatitis Market Size is projected to reach USD 5.69 Billion by 2030, growing at a CAGR of 16.5%: Straits Research

New York, United States, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Canine Atopic Dermatitis is marked by skin irritation that lasts for a long time and a particular pattern of skin lesions. IgE antibodies...
November 16, 2018 02:20 ET | Source: Biofrontera AG

Biofrontera reports earnings results for the third quarter and first nine months of 2018

Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
November 05, 2018 06:26 ET | Source: Biofrontera AG

Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results

Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
September 03, 2018 05:35 ET | Source: Biofrontera AG

Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018

Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
April 30, 2018 08:00 ET | Source: Biofrontera AG

Biofrontera Reports Full Year 2017 Financial Results

Leverkusen, Germany, April 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical...
April 12, 2018 10:53 ET | Source: Biofrontera AG

Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018

Leverkusen, Germany, April 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary...